# Cardiff Oncology

Source: https://onco.cc/companies/cardiff-oncology/  
OnCo record `cardiff-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cardiff Oncology is a San Diego biotech developing onvansertib, an oral PLK1 inhibitor that is being tested with chemotherapy and bevacizumab as first-line treatment for RAS-mutant colorectal cancer.

## Summary

Cardiff Oncology, formerly the diagnostics company Trovagene, develops onvansertib, a selective oral inhibitor of Polo-like kinase 1 licensed from Nerviano Medical Sciences. The randomised phase 2 CRDF-004 trial combines onvansertib with FOLFIRI or FOLFOX plus bevacizumab in first-line RAS-mutant metastatic colorectal cancer, after earlier studies showed higher response rates in bevacizumab-naive patients. Onvansertib has also been studied in pancreatic cancer and small cell lung cancer.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Trovagene; Cardiff Oncology, Inc.; NASDAQ:CRDF
- Tags: drug-maker
- HQ: San Diego, California
- Type: biotech
- Website: https://www.cardiffoncology.com/
- Ticker: NASDAQ:CRDF

## Sources

- Official website: https://www.cardiffoncology.com/

## Connected records

- drugs: [Onvansertib](https://onco.cc/drugs/onvansertib/)

---
JSON: https://onco.cc/api/v1/entities/cardiff-oncology.json